Author: Bougakov, Dmitri; Podell, Kenneth; Goldberg, Elkhonon
                    Title: Multiple Neuroinvasive Pathways in COVID-19  Cord-id: lf3iix8i  Document date: 2020_9_29
                    ID: lf3iix8i
                    
                    Snippet: COVID-19 is a highly infectious viral disease caused by the novel coronavirus SARS-CoV-2. While it was initially regarded as a strictly respiratory illness, the impact of COVID-19 on multiple organs is increasingly recognized. The brain is among the targets of COVID-19, and it can be impacted in multiple ways, both directly and indirectly. Direct brain infection by SARS-CoV-2 may occur via axonal transport via the olfactory nerve, eventually infecting the olfactory cortex and other structures in
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: COVID-19 is a highly infectious viral disease caused by the novel coronavirus SARS-CoV-2. While it was initially regarded as a strictly respiratory illness, the impact of COVID-19 on multiple organs is increasingly recognized. The brain is among the targets of COVID-19, and it can be impacted in multiple ways, both directly and indirectly. Direct brain infection by SARS-CoV-2 may occur via axonal transport via the olfactory nerve, eventually infecting the olfactory cortex and other structures in the temporal lobe, and potentially the brain stem. A hematogenous route, which involves viral crossing of blood–brain barrier, is also possible. Secondary mechanisms involve hypoxia due to respiratory failure, as well as aberrant immune response leading to various forms of encephalopathy, white matter damage, and abnormal blood clotting resulting in stroke. Multiple neurological symptoms of COVID-19 have been described. These involve anosmia/ageusia, headaches, seizures, mental confusion and delirium, and coma. There is a growing concern that in a number of patients, long-term or perhaps even permanent cognitive impairment will persist well after the recovery from acute illness. Furthermore, COVID-19 survivors may be at increased risk for developing neurodegenerative diseases years or decades later. Since COVID-19 is a new disease, it will take months or even years to characterize the exact nature, scope, and temporal extent of its long-term neurocognitive sequelae. To that end, rigorous and systematic longitudinal follow-up will be required. For this effort to succeed, appropriate protocols and patient registries should be developed and put in place without delay now.
 
  Search related documents: 
                                Co phrase  search for related documents- abnormal finding and acute illness: 1, 2
  - abnormal finding and acute patient: 1
  - abnormal finding and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
  - abnormal finding and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
  - abnormal finding and acute stage: 1
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date